Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis.
Julie E SteinJeffrey Patterson-FortinBenjamin E BodnarPublished in: BMJ case reports (2018)
A 44-year-old woman with cutaneous psoriasis and no history of joint involvement recently treated with adalimumab was admitted to the inpatient Internal Medicine service for uncontrolled, severe joint pain so debilitating that it limited her activities of daily living and prevented her from working as a medical technologist. She had stopped taking adalimumab 3 weeks prior to presentation after receiving approximately 2.5 months of therapy for cutaneous psoriasis unresponsive to trials of topical steroids and methotrexate. Antinuclear antibody and anti-double-stranded DNA antibodies were positive at high titres. She received a course of oral corticosteroids with improvement in her symptoms.
Keyphrases
- rheumatoid arthritis
- juvenile idiopathic arthritis
- case report
- disease activity
- healthcare
- mental health
- ulcerative colitis
- hidradenitis suppurativa
- systemic lupus erythematosus
- atopic dermatitis
- chronic pain
- palliative care
- neuropathic pain
- high dose
- high glucose
- cell free
- circulating tumor
- drug induced
- pain management
- early onset
- binding protein
- spinal cord
- spinal cord injury
- low dose
- nucleic acid
- gestational age
- preterm birth
- oxidative stress
- smoking cessation
- postoperative pain